MicroRNAs (miRNAs) modulate complex physiological and pathological processes by repressing expression of multiple components of cellular regulatory networks. Here we demonstrate that miRNAs encoded by the miR-23∼27∼24 gene clusters are enriched in endothelial cells and highly vascularized tissues. Inhibition of miR-23 and miR-27 function by locked nucleic acid-modified anti-miRNAs represses angiogenesis in vitro and postnatal retinal vascular development in vivo. Moreover, miR-23 and miR-27 are required for pathological angiogenesis in a laser-induced choroidal neovascularization mouse model. MiR-23 and miR-27 enhance angiogenesis by promoting angiogenic signaling through targeting Sprouty2 and Sema6A proteins, which exert antiangiogenic activity. Manipulating miR-23/ 27 levels may have important therapeutic implications in neovascular age-related macular degeneration and other vascular disorders.
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blindness | MAP kinase signaling | semaphorins | Akt | proangiogenic T he growth of blood vessels through angiogenesis is a delicately controlled process that involves endothelial cell (EC) activation, proliferation, migration, and maturation (1) . Physiological angiogenesis is required for normal vascular development as well as vascular homeostasis during adulthood. Pathological angiogenesis, commonly induced by tissue ischemia or inflammation, underlies numerous vascular disorders, such as age-related macular degeneration (AMD), a leading cause of blindness in the elderly (2) . Choroidal neovascularization (CNV), which involves abnormal growth of blood vessels in the back of the eye, is a hallmark of neovascular AMD (3) . Although the pathogenic mechanisms underlying AMD are still largely unknown, vascular endothelial growth factor (VEGF) has been shown to play a causal role in the development of CNV (4) . Anti-VEGF agents have demonstrated efficacy in treating CNV in neovascular AMD (5, 6) but have limited efficacy and potential side effects (7, 8) .
Recent studies have revealed important roles for microRNAs (miRNAs) in cardiovascular diseases and other disorders (9) . miRNAs are small noncoding RNAs that negatively regulate gene expression by inducing mRNA degradation or inhibiting translation through binding to the 3′ untranslated region (3′UTR) of target mRNAs (10) . Often, miRNAs modulate broad collections of mRNAs encoding multiple components of complex biological pathways. Several miRNAs have been implicated in angiogenesis (11, 12) . A group of miRNAs has also been shown to be substantially decreased in a laser-induced CNV model (13) .
The miR-23∼27∼24 clusters are highly expressed in ECs (14) (15) (16) (17) . Two miR-23∼27∼24 clusters exist in the vertebrate genome: an intergenic miR-23a∼27a∼24-2 cluster and an intronic miR23b∼27b∼24-1 cluster. Members of these clusters are involved in cell cycle control, proliferation, and differentiation of various cell types (18) . Here, we show that inhibition of miR-23/27 impairs angiogenesis in vitro and postnatal retinal vascular development in vivo. Moreover, silencing of miR-23/27 suppresses laser-induced CNV in mice. The proangiogenic functions of miR-23/27 correlate with the repression of Sprouty2 and Sema6A, which negatively regulate angiogenic signaling.
Results
Structure and Expression Pattern of miR-23∼27∼24 Cluster Members.
The mouse miR-23a∼27a∼24-2 cluster is intergenic on chromosome 8, and the miR-23b∼27b∼24-1 cluster is located in intron 4 of an alanine aminopeptidase gene on chromosome 13 (Fig. 1A) . The miR-23a∼27a∼24-2 cluster encodes a primary miRNA (pri-miRNA) transcript composed of three miRNAs: miR-23a, miR-27a, and miR-24-2, and the miR-23b∼27b∼24-1 cluster encodes a pri-miRNA transcript containing miR-23b, miR-27b, and miR-24-1 (Fig. S1A) . The mature miRNA sequences of miR-23a/b, miR-27a/b, and miR-24 are conserved among vertebrate species (Fig. S1B) . miR-23a and miR-27a differ by only one nucleotide near their 3′ ends compared with their paralogs miR-23b and miR-27b, whereas the sequence of miR-24-1 and miR-24-2 is the same (Fig. S1C ). miR-23a and miR-23b share most, if not all, predicted target genes by TargetScan and DIANA Lab, as do miR-27a and miR-27b (19, 20) .
Northern-blot analyses revealed that miR-23a/b, miR-27a/b, and miR-24 are expressed at the highest levels in the lung and heart, which are highly vascularized tissues (Fig. 1B) . Their expression is also detectable in other organs, including the eye. Realtime PCR confirmed the enrichment of the mature miRNAs of these two clusters in the lung and heart (Fig. S1D ). Real-time PCR was further performed to determine the expression of miR-23∼27∼24 cluster members in different cell types. Our results showed that the expression of all miR-23∼27∼24 cluster members is enriched in ECs compared to the other cell types tested (Fig.  1C) , consistent with previous reports (14-21) and a recent report that expression of the miR-23b∼27b∼24-1 host gene is enriched in ECs in vivo (21) . Taken together, our results indicate that miR-23∼27∼24 cluster members are enriched in ECs and highly vascularized tissues, suggesting a potential role in EC function. To study the EC function of miR-23∼27∼24 cluster members in vitro, human umbilical vein EC line (HUVECs) were transfected with locked nucleic acid (LNA)-modified anti-miRs of miR-23a/b, miR-27a/b, or a scramble control and tested for EC network formation on Matrigel. More than 90% knockdown of miR-23a/b or miR-27a/b expression was achieved by LNA-anti-miR-23a/b or anti-miR-27a/b transfection, respectively, indicating the efficiency and specificity of miRNA knockdown by LNA anti-miRs ( Fig. 2A) . Hereafter, miR-23a/b and miR-27a/b will be referred to as miR-23 and miR-27. Of note, there was compensatory up-regulation of miR-23 or miR-27 when miR-27 or miR-23 were knocked down. When cultured on Matrigel, ECs form a primary vascular network. Knockdown of miR-27, and to a lesser extent miR-23, impaired the formation of capillary-like structures in HUVECs cultured on Matrigel, as quantified by the reduced branching points upon miR-27 or miR-23 inhibition (Fig. 2 B and C) . These results suggest that miR-27 and miR-23 are required for proper capillary tube formation in vitro.
An ex vivo aortic ring assay was performed to further explore the requirement of miR-23 and miR-27 in sprouting angiogenesis (22) . Isolated aortic rings were transfected with anti-miR-23, antimiR-27, or scramble control and cultured on Matrigel with endothelial growth medium supplemented with 3% mouse serum. Normally, EC sprouts appear on the second day from the aortic rings and grow rapidly after 4-6 d of culture. Compared with the control, knockdown of miR-27, and to a lesser extent miR-23, significantly repressed the outgrowth of aortic ring cells (Fig. 2D) .
To further determine whether overexpression of miR-23 or miR-27 is sufficient to enhance sprouting angiogenesis, similar assays were performed after infection of the aortic rings with adenoviruses expressing miR-23b, miR-27b, or LacZ control. Compared with the LacZ control, overexpression of miR-27 significantly enhanced aortic ring cell outgrowth, causing an ∼30% increase in migratory distance, and miR-23 overexpression also showed a trend toward increased aortic ring cell sprouting ( Fig. 2D and Fig. S2 ).
To examine the cellular mechanism whereby miR-23 and miR-27 regulate angiogenesis, EC proliferation and migration were analyzed after LNA-anti-miR-23/27 transfection. EC proliferation upon VEGF stimulation was measured by BrDU incorporation, whereas EC migration was quantified after a scratch wound assay (23, 24) . As shown in Fig. 2E , compared with serumstarved HUVECs, VEGF induced EC proliferation by ∼3-fold in 24 h. Knockdown of miR-27 repressed VEGF-induced EC proliferation by ∼30%, and knockdown of miR-23 also showed a trend in repressing EC proliferation. Knockdown of both miR-23 and miR-27 appeared to have a synergistic effect in repressing VEGF-induced EC proliferation. When a scratch wound is created in a monolayer of cultured HUVECs, the cells migrate to the wounded region upon stimulation by VEGF. VEGF-induced EC migration was significantly repressed by miR-27 silencing and to a lesser extent by miR-23 silencing in ECs (Fig. 2F) . These results indicate that miR-23 and miR-27 enhance angiogenesis by promoting EC proliferation and migration in response to VEGF.
miR-23 and miR-27 Target Sprouty2, Sema6A, and Sema6D in ECs. To begin to elucidate the mechanisms whereby miR-23 and miR-27 regulate angiogenesis, we took a bioinformatic approach to identify signaling pathways and target genes regulated by miR-23 and miR-27. Using the DIANA-mirPath software, designed to integrate miRNA target genes into signaling pathways (25), we found that proteins involved in axon guidance (P = 0.00018) and mitogen-activated protein kinase (MAPK) signaling pathways (P = 0.034) were significantly enriched in miR-23 and miR-27 target genes (Fig. S3A ). Among the predicted target genes, we focused on Sprouty2, Semaphorin6A (Sema6A), and Semaphorin6D (Sema6D), which negatively regulate angiogenesis (26, 27) . Importantly, multiple conserved binding sites for miR23a/b and miR-27a/b are contained in the 3′UTRs of these mRNAs (Fig. S3B) , suggesting that miR-23 and miR-27 might promote angiogenesis through suppression of Sprouty2, Sema6A, and Sema6D, which exert antiangiogenic activity.
To test whether miR-23 and miR-27 directly inhibit Sprouty2, Sema6A, and Sema6D 3′UTR activity, we tested the effects of these miRNAs on expression of luciferase reporters linked to the 3′UTRs of SPROUTY2, SEMA6A, and SEMA6D mRNAs in COS cells. Overexpression of miR-23 or miR-27 significantly repressed the activity of luciferase reporters containing human SPROUTY2, SEMA6A, or SEMA6D 3′UTRs (Fig. 3A) . Moreover, the repression of the SPROUTY2 3′UTR by miR-23 and miR-27 was dependent on their targeting sites, because mutation of either the miR-23 target sites or the miR-27 target site in the SPROUTY2 3′UTR attenuated the repression by miR-23 or miR-27, respectively (Fig. 3A) .
To examine whether miR-23 and miR-27 could repress the expression of endogenous SPROUTY2, SEMA6A, or SEMA6D proteins, HUVECs were infected with adenovirus expressing miR23b and/or miR-27b, or LacZ as control, and SPROUTY2, SEMA6A, or SEMA6D protein expression was examined by Western blot. As shown in Fig. 3B , overexpression of miR-23b or miR-27b repressed SPROUTY2, SEMA6A, and SEMA6D proteins, whereas overexpression of miR-23b and miR-27b showed a synergistic effect in repressing the expression of these proteins. Next, we transfected HUVECs with LNA-anti-miRs of miR-23 and/or miR-27, or scramble control, and similarly examined the expression of these proteins. We observed a significant increase in the expression of SPROUTY2, SEMA6A, and SEMA6D expression upon miR-23 or miR-27 knockdown (Fig. 3B) . These results indicate that miR-23 and miR-27 mediate the repression of SPROUTY2, SEMA6A, and SEMA6D expression in ECs.
Sprouty proteins function as intracellular inhibitors of the Ras/ Raf/ERK pathway (28) . Semaphorin proteins can provide directional cues for cell migration by modulating VEGF signaling pathways (27, 29) . To test whether miR-23 and miR-27 are required for regulating angiogenic signaling pathways, HUVECs were transfected with LNA-anti-miR-23/27 or scramble control, and phospho-AKT and phospho-ERK1/2, indicative of AKT and MAPK activities, were measured. Phosphorylation of ERK1/2 and AKT was significantly decreased by miR-23 and miR-27 knockdown in ECs without affecting total ERK1/2 and AKT levels (Fig.  3C) . Anti-miR-23/27 or control transfected HUVECs were further tested for ERK1/2 phosphorylation in response to VEGF. As shown in Fig. 3D , ERK1/2 phosphorylation was strongly induced in HUVECs upon VEGF treatment. Knockdown of miR-23 and miR-27 repressed ERK1/2 phosphorylation induced by VEGF, consistent with the up-regulation of the miR-23/27 target protein SPROUTY2, which inhibits the RAS/RAF/ERK pathway. SEMA6A inhibits EC migration (27) . To test whether the upregulation of SEMA6A contributes to the decreased angiogenic signaling upon miR-23/27 knockdown, HUVECs were incubated with SEMA6A recombinant protein, treated with VEGF, and tested for angiogenic signaling activities. As shown in Fig. 3E , SEMA6A significantly repressed the phosphorylation of VEGFR2 and ERK1/2 in response to VEGF, whereas VEGFR2 and ERK1/ 2 proteins remained unchanged. These results support the conclusion that miR-23 and miR-27 are required for modulating VEGFR2 and MAPK signaling in response to VEGF through repressing SPROUTY2 and possibly SEMA6A.
We further asked whether Sprouty2 can mediate the angiogenic effects of miR-23 and 27. Aortic ring assays were performed to examine whether knockdown of Sprouty2 by siRNA could rescue the sprouting defects caused by miR-23/27 silencing. Western blot analysis confirmed the efficient Sprouty2 knockdown in the cultured aortic rings (Fig. 3F) . The results showed that Sprouty2 knockdown rescued the sprouting defects caused by miR-23/27 silencing, indicating that Sprouty2 plays a major role in mediating miR-23/27 angiogenic effects (Fig. 3G and Fig. S4 ). 
Regulation of Retinal Vascular Development by miR-23 and miR-27 in
Vivo. To further address the role of miR-23 and miR-27 in angiogenesis in vivo, we performed miRNA loss-of-function studies in neonatal mouse retinas, a well-established model of angiogenesis (30) . Vascularization of the outer retina commences at postnatal d 0 (P0) from the central retinal artery, and the ECs sprout to reach the peripheral region at about P8. Anti-miRs targeting miR-23 and miR-27, or scramble control, were injected intravitreously into the eye at P2, and retinas were isolated at P6 for RNA, protein, and flat mount staining of the developing retinal vasculature (Fig. 4A) . Subretinal injection of LNA-antimiR-23/27 resulted in >90% reduction in retinal miR-23/27 levels compared with the controls (Fig. 4B) . Of note, compensatory upregulation of miR-24 was observed (Fig. 4B) . Thus, LNA-antimiRs displayed high efficacy and specificity in the retina in vivo.
To examine the effect of miR-23/27 knockdown on postnatal retinal vascular development, P6 retinal flat mounts were stained with intercellular adhesion molecule-2 (ICAM-2) to visualize the vessels. Scramble LNAs did not affect retinal vascular development compared with the noninjection controls, based on ICAM-2 staining. However, in anti-miR-23/27-injected retinas, there was an ∼10% decrease in sprouting distance and an ∼20% decrease in vascular coverage at 4 d after anti-miR-23/27 injection compared with the controls (Fig. 4 C and D) . At higher magnification, fewer newly formed vessel sprouts were observed in the anti-miR-23/27-injected retinas compared with the controls (Fig.  4C, c and d) . During retinal vascular development, ECs sprout along glial fibrillary acidic protein (GFAP)-positive astrocytes. GFAP staining indicated that astrocyte coverage was not affected by miR-23/27 knockdown (Fig. 4C, e and f) , suggesting that the retinal EC sprouting phenotype evoked by miR-23/27 knockdown is not secondary to potential astrocyte defects. Moreover, consistent with our in vitro results, miR-23 and miR-27 target proteins, Sprouty2, Sema6A, and Sema6D, were significantly up-regulated upon miR-23/27 knockdown in the retinas (Fig. 4E) . Taken together, our results indicate that miR-23 and miR-27 modulate retinal vascular development in vivo.
Requirement of miR-23 and miR-27 in CNV in Vivo. The angiogenic defects resulting from miR-23 and miR-27 knockdown in vitro and in vivo suggested that miR-23 and miR-27 might play an important role in neovascularization in response to injury. We adopted a laser-induced CNV mouse model, the most reliable CNV animal model, to test the role of miR-23 and miR-27 in CNV (31) . We first examined the expression of miR-23∼27∼24 clusters in the retina/choroid after laser injury. Adult C57BL/6 mice were subjected to rupture of Bruch's membrane in six locations by laser photocoagulation (140 mV, 100 ms, 100 μm) (32) . As demonstrated by real-time PCR, miR-23a, miR-27a, and miR-24 levels were significantly up-regulated, and miR-23b and miR-27b expression was also increased in the retinal/choroidal region at 1 wk after laser injury (Fig. 5A) .
To directly test the requirement of miR-23/27 in CNV, LNAanti-miRs targeting miR-23 and miR-27, or scramble control, were intravitreously injected to knockdown miR-23 and miR-27 in the eye immediately following laser injury in three locations (Fig. 5B) . A secondary injection was performed on the following day to ensure efficient knockdown. Eyes were collected at 2 wk after laser injury for ICAM-2 staining and confocal imaging (33) . As shown in Fig. 5C , >90% knockdown efficiency of miR-23 and miR-27 in the retina/choroid/sclera was achieved by anti-miR injection compared with the controls. Of note, we observed an upregulation of miR-23∼27∼24 members after scramble control injection compared with noninjection controls, possibly reflecting the increased inflammatory response due to injection. We tested anti-platelet/endothelial cell adhesion molecule (PECAM)-1 antibody, isolectin-B4, and FITC-dextran staining besides anti-ICAM-2 staining and found ICAM-2 gave the best staining for CNV, consistent with a recent report (33) . Quantification of the CNV area, as shown by ICAM-2 staining, revealed that silencing of miR-23 and miR-27 repressed the CNV area by >50% compared with scramble control (Fig. 5 D and F) . The repression of CNV by miR-23/27 was also confirmed by ICAM-2 staining of the lesion sections (Fig. 5E) . Compared with the noninjection controls, we observed a mild increase in CNV in scramble-injected samples, possibly due to increased CNV induced by miR∼23∼27∼24 upregulation (Fig. S5B) . Taken together, our data indicates that miR-23 and miR-27 are required for laser-induced CNV in vivo.
Discussion
The findings of this study reveal an important role for miR-23 and miR-27 in angiogenesis and CNV (Fig. 6) . We provide evidence that silencing of miR-23 and miR-27 represses sprouting angiogenesis in vitro and in vivo, as well as CNV in a laser-induced CNV mouse model. The proangiogenic actions of miR-23 and miR-27 correlate with the repression of their target mRNAs encoding Sprouty2 and Sema6A, which negatively regulate MAPK and VEGFR2 signaling in response to angiogenic factors. Thus, in the absence of miR-23 and miR-27, Sprouty2 and Sema6A proteins are up-regulated, with consequent dampening of MAPK and VEGFR2 signaling. Conversely, overexpression of miR-23 and miR-27 represses these targets, relieving their repressive influence on these pathways. It seems that miR-27 has a more dominant role in angiogenesis than miR-23, as shown by more severe miR-27 knockdown/overexpression phenotypes in the Matrigel and aortic ring assays. miR-24 has been shown to regulate apoptosis and inhibit cell proliferation (34, 35) . In the absence of miR-23 and miR-27, there is a compensatory up-regulation of miR-24 in our in vitro and in vivo knockdown assays (Fig. 4B) . The potential role of miR-24 in angiogenesis awaits future studies. (36) . Axon guidance and MAPK signaling are highly ranked as the biological processes regulated by both miR-23 and miR-27. It is noteworthy, in this regard, that axon guidance molecules commonly affect EC behavior similarly, accounting for the similar patterning of both blood vessels and nerves (37) , and MAPK pathways have been shown to regulate angiogenesis. Among the predicted target genes in these pathways, Sprouty proteins function as intracellular inhibitors of the MAPK pathway. Sema6A has also been reported to repress angiogenic signaling (27) . We show that both miR-23 and miR-27 directly target the SPROUTY2 and SEMA6A 3′UTRs for repression. The identification of Sprouty2 as a target for both miR-23 and miR-27 is consistent with a recent report that Sprouty2 is a target for miR-27a during cancer cell growth and migration (38) . The inhibitory actions of Sprouty proteins are mediated by interference of phosphorylation and activation of Raf, an upstream activator of the MAPK pathway. Repression of Sprouty2 by miR-23 and miR-27 at least partially underlies the mechanism whereby miR-23 and miR-27 enhance MAPK pathway activation in response to VEGF. sema6A may also contribute to the regulation of MAPK and PI3K-AKT signaling by miR-23 and miR-27, likely through repressing VEGFR2 signaling. Knockdown of Sprouty2 rescued the sprouting defects imposed by miR-23/27 silencing in cultured aortic rings, indicating a major role for Sprouty2 in mediating miR-23/27 angiogenic function. Because miR-23 and miR-27 have hundreds of predicted target genes, the angiogenic function of these miRNAs likely reflects the combined effects of multiple target genes.
miR-23∼27∼24 Cluster Members in CNV. Inflammation and angiogenesis play pivotal roles in CNV, the major cause of vision loss in patients with AMD (39, 40) . Our results show that miR-23∼27∼24 cluster members are up-regulated in CNV (Fig. 6A ). This correlates with the up-regulation of miR-23∼27∼24 cluster members by proinflammatory stimuli (Fig. S5A) (41, 42) , suggesting a role for miR-23∼27∼24 cluster members in linking inflammation to angiogenesis in CNV. Indeed, miR-27b was recently shown to contribute to LPS-mediated inflammation by targeting PPAR-γ (41). Our finding that silencing of miR-23 and miR-27 represses laserinduced CNV indicates that miR-23∼27∼24 cluster members indeed play a causative role in CNV. However, how miR-23, -27, and -24 regulate inflammation in CNV is yet to be investigated. Because miR-23∼27∼24 clusters are highly conserved from mice to humans, therapeutic manipulation of miR-23/27 represents a potential strategy in treating CNV in patients with neovascular AMD and other vascular diseases. The identification of miR-23 and miR-27 as important regulators of MAPK activation also suggests roles for these miRNAs in cancer.
Materials and Methods
LNA-Anti-miRs, Pre-miR Precursors, siRNAs, and miRNA expressing adenoviruses. LNA-anti-miRs for miR-23a/b, miR-27a/b, or scramble controls for in vitro and in vivo studies were synthesized from Exiqon. SiRNAs for SPROUTY2 were synthesized from Dharmacon. Sequences for SPROUTY2 siRNA, in vitro and in vivo LNA-anti-miRs, are described in SI Materials and Methods. Ambion pre-miR miRNA precursor of hsa-miR-23b, hsa-miR-27b, or negative control was synthesized from Applied Biosystem. Adenovirus expressing miR-23b, miR-27b, or lacZ was generated from mouse genomic DNA encoding miR-23b or miR-27 as described (24) .
Cell Culture, Cell Proliferation, Scratch-Wound, In Vitro Matrigel, and Aortic Ring Sprouting Assay. HUVEC cell culture, cell proliferation, scratch-wound, in vitro Matrigel assays, as well as aortic ring sprouting assays are described in SI Materials and Methods.
RNA, Western Blot Analysis, and Reporter Assay. RNA isolation, real-time RT-PCR, Western blot analysis, and reporter assays were performed according to standard procedures. Detailed methods are outlined in SI Materials and Methods.
Neonatal Retinal Injection, Postnatal Retinal Angiogenesis, and Laser-Induced CNV. In vivo injection in the mouse retina was performed primarily as described (43) . Laser photocoagulation was induced in 6-to 8-wk-old male C57BL/6J mice as described (32) . Detailed protocols are summarized in SI Materials and Methods.
Institutional Compliance and Animal Care. All experiments using animals were approved by the Institutional Animal Care and Use Committee at University of Texas Southwestern Medical Center.
